ArticleFrontiers in pharmacology2021

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.

Eduardo Huarte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.